

Division of Research Grants; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meeting:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Multidisciplinary Sciences.

Date: April 7, 1995.

Time: 9:30 a.m.

Place: Hyatt Regency, Bethesda, MD.

Contact Person: Dr. Catharine Wingate, Scientific Review Admin. 5333 Westbard Avenue, Room 357, Bethesda, MD 20892, (301) 594-7295.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 14, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, National Institutes of Health.

[FR Doc. 95-6852 Filed 3-20-95; 8:45 am]

BILLING CODE 4140-01-M

Opportunity For a License: Live, Attenuated Bovine Parainfluenza Virus Type 3 (BPIV-3) for Use as a Vaccine to Protect Infants and Children Against Disease(s) Caused by Human Parainfluenza Virus Type 3 (HPIV-3)

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health (NIH), Department of Health and Human Services (DHHS), seeks licensee(s) who can effectively pursue the clinical and commercial development of a live, attenuated BPIV-3 vaccine. Several common childhood acute respiratory illnesses, including croup, pneumonia and bronchiolitis, are caused by HPIV-3 viral infection. Briefly, the National Institute of Allergy and Infectious Diseases (NIAID) has supported the clinical research development of this experimental

vaccine in a series of phase I trials and has evidence that this candidate live virus could be used as a safe and immunogenic pediatric vaccine against HPIV-3. The NIAID is interested in having these efforts utilized for the public good, as mandated by the Federal Technology Transfer Act (FTTA) of 1986, by transferring certain unpatented biological materials to a company. For consideration, prospective licensee(s) should be capable of further developing and eventually commercializing a live attenuated BPIV-3 vaccine. Furthermore, the prospective industrial partner should have: An aggressive clinical development plan for BPIV-3; access to suitably equipped manufacturing facilities for large-scale production of the candidate vaccine; relevant experience in obtaining regulatory approval for other vaccines. NIAID scientists would provide the relevant BPIV-3 viral strains as well as supply information and data from the completed phase I clinical studies. This information is available for confidential evaluation to interested parties following the acceptance of standard confidentiality terms. The deadline for submitting a license application will be 90 days from March 21, 1995.

ADDRESSES: Requests for a summary of the clinical trial results and additional scientific information about the BPIV-3 vaccine as well as other questions and comments concerning clinical aspects this technology should be directed to: Claire T. Driscoll, Technology Transfer Specialist, Technology Transfer Branch, NIAID, NIH, Building 31, Room 7A32, 9000 Rockville Pike, Bethesda, MD 20892. Telephone (301) 496-2644; E-mail: Claire.Driscoll@d31.niaid.pc.niaid.nih.gov; Fax (301) 402-7123.

Requests for a copy of the license application form, or other questions and comments concerning the licensing of this technology should be directed to: Steven M. Ferguson, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804. Telephone (301) 496-7735 extension 266; E-mail: fergusos@od6100m1.od.nih.gov; Fax (301) 402-0220.

Dated: March 13, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95-6853 Filed 3-20-95; 8:45 am]

BILLING CODE 4140-01-P

Public Health Service**National Center for Health Statistics**

AGENCY: National Center for Health Statistics, DHHS.

ACTION: Notice of meeting.

SUMMARY: The ICD-9-CM Coordination and Maintenance Committee (C&M) will be holding its first meeting of the year on Friday May 5, 1995. The C&M meeting is a public forum for the presentation of proposed modifications to the International Classification of Diseases, ninth-revision, clinical modification.

DATES: The meeting will be held on May 5, 1995 from 9:00 a.m.-5:00 p.m.

ADDRESSES: The Hubert H. Humphrey Building, rm. 703A, 200 Independence Avenue, Washington, DC.

FOR FURTHER INFORMATION CONTACT: Amy Blum, 301-436-4216.

SUPPLEMENTARY INFORMATION: Tentative agenda:

Tobacco related illness Coordination disorders
Concussion versus Head Injury NOS
Chlamydial Pneumonia Atherosclerosis
Late Amputation Stump Complications
Laparoscopic Appendectomy
Development of ICD-10 Procedure Classification
Addenda

Sue Meads,

Co-chair, ICD-9-CM Coordination and Maintenance Committee.

[FR Doc. 95-6884 Filed 3-20-95; 8:45 am]

BILLING CODE 4160-18-M

Substance Abuse and Mental Health Services Administration**Supplemental Awards for Addiction Training Centers Grantees**

AGENCY: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

ACTION: Availability of supplemental funds for currently funded grantees in the Center for Substance Abuse Treatment (CSAT) addiction training centers cooperative agreement program.

SUMMARY: This notice is to inform the public that CSAT is making available approximately \$1.7 million for supplemental awards in fiscal year 1995 to existing grantees in its Addiction Training Centers (ATCs) program. Competition is being limited to the eleven currently funded ATCs because their unique training infrastructure is well established and will permit the additional activities described below to